Neil is an experienced biotechnology professional with expertise in commercialising technology in the areas of biomarker, target and drug discovery. In 2009, together with researchers from Bart’s Cancer Institute, Neil was involved in founding Activiomics Ltd, a proteomics company where he served as Chief Operating Officer until its acquisition by Retroscreen Virology (now hVIVO) in 2014. Subsequently Neil was engaged in the establishment of R&D activities with hVIVO as Director of Discovery Research.
Previously, Neil worked at Piramed Pharma, where he involved in the management of a successful research collaboration with Genentech focused on the discovery and development of PI3-kinase inhibitors for cancer. Neil holds a BSc in Biology from the University of York and a PhD from the Protein Phosphorylation laboratory at the Cancer Research UK London Research Institute. He also completed Post-Doctoral training at the University of California San Francisco Cancer Center.